使用Impella LP 5.0成功治疗急性移植排斥所致心力衰竭。
Successful treatment of heart failure due to acute transplant rejection with the Impella LP 5.0.
作者信息
Samoukovic Gordan, Al-Atassi Talal, Rosu Cristian, Giannetti Nadia, Cecere Renzo
机构信息
Division of Cardiothoracic Surgery, McGill University Health, Montreal, Quebec, Canada.
出版信息
Ann Thorac Surg. 2009 Jul;88(1):271-3. doi: 10.1016/j.athoracsur.2008.12.036.
Cardiogenic shock resulting from transplant rejection is a serious complication with high mortality and morbidity. Often resistant to maximal medical therapy, this condition frequently requires mechanical circulatory support until recovery or retransplantation. We present a 52-year-old patient with multiorgan failure secondary to acute graft rejection after orthotopic heart transplantation. Maximal medical therapy was not successful, and the patient was bridged to recovery with an Impella LP 5.0 (Abiomed Inc, Danvers, MA) left ventricular assist device (LVAD). The relative merits of this therapeutic approach are outlined and discussed. The patient was discharged 3 weeks after LVAD removal and remains clinically stable.
移植排斥反应导致的心源性休克是一种严重的并发症，死亡率和发病率都很高。这种情况通常对最大程度的药物治疗有抵抗性，常常需要机械循环支持直到恢复或再次移植。我们报告一例52岁患者，在原位心脏移植后因急性移植物排斥反应继发多器官功能衰竭。最大程度的药物治疗未成功，该患者通过一台Impella LP 5.0（美国马萨诸塞州丹弗斯市的Abiomed公司）左心室辅助装置（LVAD）过渡到恢复阶段。本文概述并讨论了这种治疗方法的相对优点。该患者在LVAD移除3周后出院，目前临床状况稳定。
Zotero 插件